Jaguar Health Inc (NASDAQ:JAGX) was the target of a large increase in short interest in September. As of September 28th, there was short interest totalling 1,862,267 shares, an increase of 196.9% from the September 14th total of 627,256 shares. Based on an average daily trading volume, of 6,779,325 shares, the short-interest ratio is presently 0.3 days. Approximately 23.5% of the shares of the stock are short sold.
JAGX stock opened at $0.51 on Friday. The company has a quick ratio of 0.33, a current ratio of 0.56 and a debt-to-equity ratio of 0.77. Jaguar Health has a one year low of $0.50 and a one year high of $6.60.
An institutional investor recently bought a new position in Jaguar Health stock. Acadian Asset Management LLC purchased a new position in Jaguar Health Inc (NASDAQ:JAGX) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 99,557 shares of the biotechnology company’s stock, valued at approximately $141,000. Acadian Asset Management LLC owned approximately 1.14% of Jaguar Health at the end of the most recent reporting period. 5.45% of the stock is owned by hedge funds and other institutional investors.
Jaguar Health Company Profile
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.